RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.
Article in Aging (August 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Aging (August 2024)
Article in Frontiers in Microbiology (May 2024)